Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTR2TXZ)

• DTT Name: Jun N terminal kinase (JNK) DTT Info
• UniProt ID: MK08_HUMAN; MK09_HUMAN; MK10_HUMAN
• Gene Name: MAPK8; MAPK9; MAPK10

Molecule-Related Drug & Molecule List

4 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AM-111	DM4E9PK	Neurological disorder	6B60	Phase 3	[1]
BGP-15	DMYDM68	Type-2 diabetes	5A11	Phase 2	[2]
CC-401	DMPMO6G	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3], [4]
CC-930	DMHVEGJ	Discoid lupus erythematosus	EB51.0	Phase 2	[5]

2 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID25991433-Compound-O1	DMH073T	N. A.	N. A.	Patented	[6]
PMID25991433-Compound-Q1	DMEMSB2	N. A.	N. A.	Patented	[6]

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One	DMDN12L	Discovery agent	N.A.	Investigative	[7]

References

• [1] The JNK inhibitor XG-102 protects against TNBS-induced colitis.PLoS One.2012;7(3):e30985.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Signal integration by JNK and p38 MAPK pathways in cancer development.Nat Rev Cancer.2009 Aug;9(8):537-49.
• [4] Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents.Chem Biol.2014 Nov 20;21(11):1433-43.
• [5] In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism. Xenobiotica. 2015;45(6):465-80.
• [6] c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
• [7] c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001 Jul;108(1):73-81.